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ABSTRACT 
Objectives 
To explore the outcome domains and measurement instruments reported across randomized 
trials of any interventions for various shoulder disorders. 
Methods 
We searched for shoulder trials included in Cochrane reviews published up to Issue 10, 2015, 
or indexed in PubMed between 2006 and 2015. Trials were eligible for inclusion if they 
focused on any intervention for rotator cuff disease, adhesive capsulitis, shoulder instability, 
glenohumeral or acromioclavicular osteoarthritis, shoulder dislocation, proximal humeral or 
humeral head fractures, or unspecified shoulder pain. Two authors independently selected 
trials for inclusion and extracted information on the domains and measurement instruments 
reported, with consensus discussion among all authors where required. 
Results 
We included 409 trials, published between 1954 and 2015. Across the trials, we identified 
319 different instruments that were classified into 32 domains. Most trials reported a measure 
of pain (90%), range of motion (78%), and physical function (71%). Measurement of adverse 
events was reported in only 31% of trials. Muscle strength was reported in 44% of trials and 
imaging outcomes were reported in 21% of trials. Other patient-reported outcome measures 
such as global assessment of treatment success, health-related quality of life, work ability, 
and psychological functioning, were each reported in 15% or fewer trials. Most domains were 
reported at a similar frequency across different shoulder disorders. 
Conclusion 
There was wide diversity in the domains and measurement instruments reported. Our results 
provide the foundation for the development of a core outcome set for use in future trials 
across all shoulder disorders. 
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SIGNIFICANCE AND INNOVATIONS 
 Across 409 trials for various shoulder disorders (e.g. rotator cuff disease, adhesive 
capsulitis, shoulder instability, proximal humeral/humeral head fracture), we identified 
319 measurement instruments that were classified into 32 domains – diversity so 
extensive that the ability to compare and synthesise the results of shoulder trials is 
severely hampered. 
 The most common domains, consistently measured across all trials, were pain (90%), 
range of motion (78%) and physical function (71%), while other patient-reported outcome 
measures such as global assessment of treatment success, health-related quality of life, 
work ability, and psychological functioning, were each reported in 15% or fewer trials. 
 Most domains were reported at a similar frequency across the different shoulder 
disorders, which suggests that it would be appropriate to develop a single core outcome 
set for all shoulder disorders.  
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Shoulder pain is a significant cause of morbidity and disability in the general population (1, 
2), with an estimated point prevalence ranging from 7 to 26% (3). The most common cause of 
shoulder pain is rotator cuff disease, while less common causes include adhesive capsulitis, 
glenohumeral osteoarthritis, and instability or dislocations/fractures resulting from sport 
injuries in young adults (1, 4, 5). Although the causes of shoulder pain vary, there is strong 
commonality in endpoints, with most patients presenting with pain that disrupts sleep 
patterns, hampers the performance of daily activities such as dressing and bathing, and 
negatively impacts on recreation and work ability (6, 7). Further, the impact of persisting 
shoulder pain on earnings, missed workdays and disability payments, is substantial (8, 9). 
 
Decisions makers often rely on the results of clinical trials to guide treatment decisions. 
However, it is not ideal if the outcomes that are measured have poor or unproven 
measurement properties, and if they vary across trials and hence cannot be compared or 
synthesized in meta-analyses (10-12). A promising strategy to reduce variation in outcome 
measurement is the development of core outcome sets (COSs) (12). This involves defining a 
set of outcome domains (constructs such as pain and function) that should be measured at a 
minimum in all trials for a particular condition, and then defining the measurement 
instruments that must be administered to cover a corresponding domain (13). COSs and their 
recommended measurement instruments have been developed for many musculoskeletal 
conditions (14), including rheumatoid arthritis (11, 15), low back pain (16) and gout (17), but 
not yet for shoulder disorders.  
 
The lack of a COS for shoulder disorders may have contributed to the wide diversity in 
measurement observed in a review of 171 trials of physical therapy interventions for rotator 
cuff disease, adhesive capsulitis and unspecified shoulder pain (18). However, it is unclear 
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whether the diversity observed in that review is similar in trials for other shoulder disorders 
(e.g. shoulder instability, glenohumeral osteoarthritis) and for other interventions (e.g. 
glucocorticoid injections, tendon repair surgery). It is possible that other domains that are 
important to patients have been measured in trials of interventions other than physical 
therapy. Investigating the outcomes measured in a broader sample of shoulder trials should 
provide a stronger foundation for the development of a COS for use in future trials for all 
shoulder disorders. 
 
The aim of this review was therefore to expand the previous review of physical therapy trials 
by exploring the frequency of outcome domains and measurement instruments reported 
across randomized trials of all interventions for a wider array of shoulder disorders. We also 
investigated whether reporting of domains varied by disorder. 
 
MATERIALS AND METHODS 
The methods for our literature review were pre-specified in a study protocol (19). 
 
Eligibility criteria   
We included randomized and quasi-randomized controlled trials investigating the effects of 
any intervention for one of the following shoulder disorders: rotator cuff disease (an umbrella 
term to classify disorders of the rotator cuff, including subacromial impingement syndrome, 
rotator cuff tendinopathy or tendinitis, partial or full rotator cuff tear, calcific tendinitis and 
subacromial bursitis (20)), adhesive capsulitis, shoulder instability, glenohumeral or 
acromioclavicular osteoarthritis, dislocation of the shoulder, proximal humeral or humeral 
head fractures, or unspecified shoulder pain. Since criteria used to diagnose shoulder 
disorders is not uniform across previous trials (4, 21), we included trials if they used any of 
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the labels specified above, rather than basing inclusion on specific diagnostic criteria. We 
excluded trials that enrolled patients with systemic inflammatory conditions such as 
rheumatoid arthritis, hemiplegia causing secondary shoulder pain, or pain in the shoulder 
region as part of a complex myofascial neck/shoulder/arm pain condition (e.g. complex 
regional pain syndrome). Trials were eligible if they compared any active intervention (e.g. 
manual therapy, surgery, glucocorticoid injection) to placebo, no treatment, or another active 
intervention. We only included completed trials, which were published and written in 
English.  
 
Search methods   
We used three approaches to identify trials. We included all trials examined in the previous 
review of domains and instruments used in physical therapy trials (18). We searched the 
Cochrane Database of Systematic Reviews (up to Issue 10, 2015) and screened the list of 
included studies in all Cochrane reviews of interventions for shoulder disorders. We also 
searched PubMed (January 2006 to December 2015) to identify recently published trials that 
may not have been included in the Cochrane reviews. The full Boolean search strategies for 
both databases are presented in online supplementary file 1.  
 
Selection of trials   
One author (either MJP or HH) screened all titles and abstracts against the eligibility criteria. 
The full text of articles assumed to be eligible, or with uncertain eligibility, were retrieved 
and screened independently by both authors. Discrepancies were resolved through discussion.  
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Data extraction and management   
Data from Cochrane reviews and the PubMed-indexed trials were extracted by one author 
(either MJP or HH) and verified by another. Discrepancies were resolved through discussion 
until consensus was reached. Data were extracted from the ‘Characteristics of included 
studies table’ of each Cochrane review (which include detailed information on the domains 
and instruments reported in each trial), or from the full text report of each PubMed-indexed 
trial. We recorded for each trial the year of publication, diagnostic label used, sample size, 
intervention under investigation (for head-to-head trials, we recorded the first intervention 
mentioned in the objectives of the trial), and all outcome measurement instruments described 
either in the Methods or Results section of the paper. As defined by the Outcome Measures in 
Rheumatology (OMERACT) Filter 2.0, a measurement instrument could be a single question, 
a questionnaire, a score obtained through physical examination, a laboratory measurement, or 
a score obtained through observation of an image (13). If results of trials had been reported in 
multiple journal articles, we extracted data from the trial as a unit by incorporating 
information from all corresponding articles. Once data extraction was complete, the dataset 
was combined with the dataset used in the previous review of physical therapy trials (18).  
 
Classification of outcome measurement instruments into domains 
One author (MJP or HH) classified each reported outcome measurement instrument under the 
domain that its developers originally designed it to address. If the instrument was unknown to 
the authors, classification was guided by retrieving the article that first described the content 
or measurement properties of the instrument. One author (MJP) then classified each domain 
under one of the four ‘Areas’ of the OMERACT Filter 2.0: Life Impact (e.g. quality of life, 
activities of daily living), Resource Use (e.g. health care visits and associated costs), 
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Pathophysiological Manifestations (e.g. changes in body function and structure that 
accompany a condition), and Mortality (13). The same author classified domains using the 
International Classification of Functioning, Disability and Health (ICF) conceptual model 
developed by the World Health Organization (22). Two authors with expertise in shoulder-
specific measurement instruments (RB and JG) verified all classifications for 
appropriateness. 
 
Statistical analyses 
We summarised results using frequencies and percentages for binary outcomes, and medians 
and interquartile ranges (IQRs) for continuous outcomes. Frequency of outcome domains was 
calculated for the complete set of trials and for trials sub-grouped by shoulder disorder 
(namely, rotator cuff disease, adhesive capsulitis, shoulder instability, 
glenohumeral/acromioclavicular osteoarthritis, shoulder instability, and 
fractures/dislocations; the latter were grouped together given their similar etiology). Analyses 
were undertaken using the statistical package Stata version 13 (23). 
 
RESULTS 
The inclusion criteria were met by 121 trials included in 18 Cochrane reviews, and 117 
PubMed-indexed trials, which were combined with the 171 physical therapy trials evaluated 
in the previous review (18). Therefore, we evaluated 409 unique trials in total (Figure 1). The 
trials were published between 1954 and 2015 (Table 1). Most trials were for rotator cuff 
disease (186/409 [45%]), followed by adhesive capsulitis (97/409 [24%]), and shoulder 
instability or proximal humeral/humeral head fracture (both in 31/409 [8%] of trials). There 
were 18 types of intervention under investigation across the trials. Manual therapy or exercise 
(delivered alone or in combination) was the most common intervention (140/409 [34%]), 
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followed by surgery (104/409 [25%]), electrotherapy modalities (such as therapeutic 
ultrasound) (65/409 [16%]), and glucocorticoid injection (45/409 [11%]). Trials included a 
median of 50 (IQR 38-75) participants. 
 
Across the trials, we identified 319 different instruments that were classified into 32 domains. 
The majority of trials included a measure of pain (368/409 [90%]), range of motion (320/409 
[78%]), and physical function (289/409 [71%]). Measurement of adverse events (serious or 
non-serious) was reported in only 126/409 (31%) trials. A measure of muscle strength was 
reported in 178/409 (44%) trials, and a radiographic outcome (i.e. any measure of the 
structure of the bones/joints/tendons evaluated via imaging) was reported in 86/409 (21%) 
trials. Other domains (e.g. global assessment of treatment success, health-related quality of 
life, work ability, health care service use, psychological functioning) were each reported in 
15% or fewer trials. Assessment of the number of deaths was reported in only 13/409 (3%) 
trials.  
 
Using the OMERACT Filter 2.0, 11 domains were classified under the Life Impact Area 
(including pain, physical function, global assessment of treatment success; Table 2). Fifteen 
domains were classified under the Pathophysiological Manifestations Area (including range 
of motion, muscle strength, and radiographic outcomes; Table 3). Four domains were 
classified under the Resource Use Area (e.g. health care services, work productivity; Table 
4). Number of deaths and adverse events do not fall under these three Areas, but make up the 
last two domains. Using the ICF conceptual model, all of the domains in Table 2 fall under 
the Activities and Participation domains, while all of the domains in Table 3 fall under the 
Body Functions and Body Structures domains. 
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A wide range of instruments was used to measure the same outcome across the included trials 
(online supplementary Table S1). Pain was measured by 47 different instruments, which 
varied in terms of the  type of pain addressed (e.g. night pain intensity, pain at rest or with 
activity), descriptor for the maximum score on the scale (e.g. “intolerable pain”, “worst pain 
imaginable”), and period of interest (e.g. “pain within the last 24 hours” versus “pain within 
the last week”). The most common was overall pain measured using a visual analogue scale 
(VAS) (174/409 trials [43%]). There were 49 different measures of physical function, and of 
these, the Constant-Murley score (24) was used most often (128/409 trials [31%]), followed 
by the Shoulder Pain And Disability Index (SPADI) (25) (49/409 trials [12%]). Nearly all 
(44/49 [90%]) of these instruments were patient-reported outcome measures (PROMs), while 
four instruments (including the Constant-Murley score and ASES score) include physician-
observed measures of functional impairment. Radiography was used to measure various 
structural outcomes, such as rotator cuff repair integrity, subluxation (partial dislocation), 
acromiohumeral distance and presence of calcific deposits. Of the measures of muscle 
strength, most were performed using a dynamometer to measure isokinetic or isometric 
strength in different positions (e.g. strength in flexion, strength in abduction). Range of 
motion was measured using either a goniometer or tape measure, although there was variation 
in the type of movements assessed (e.g. flexion, extension, abduction), the number of 
movements assessed, and whether movements were active or passive. Other domains were 
each assessed by a median of three instruments (range 1-12). 
 
 Most domains (24/32 [75%]), including pain, physical function and range of motion, were 
reported at a similar frequency across the different shoulder disorders (Figure 2, online 
supplementary Table S2). Exceptions to this included: trials for adhesive capsulitis less 
frequently reported a measure of muscle strength; trials for shoulder fracture/dislocation more 
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frequently reported a measure of adverse events, number of deaths, radiographic outcomes, 
requiring re-operation and failure of surgery; trials for osteoarthritis more frequently included 
a measure of radiographic outcomes; and trials for shoulder instability more frequently 
included a measure of instability and recreation/leisure activities.  
 
DISCUSSION 
We found that the outcome domains and measurement instruments in trials of many different 
interventions for several shoulder disorders are widely diverse. Across the trials we identified 
319 different instruments which were classified into 32 domains. Most trials included a 
measure of pain (90%), range of motion (78%), and physical function (71%). Measurement 
of muscle strength was reported in 44% of trials and measurement of radiographic outcomes 
was reported in 21% of trials. Other domains, particularly patient-reported outcome measures 
(PROMs) such as global assessment of treatment success, health-related quality of life, work 
ability, and psychological functioning, were each reported in 15% or fewer trials. There were 
47 different measurement instruments for pain and 49 for function across the trials; nearly all 
of the latter were PROMs. Most domains were reported at a similar frequency across the 
different shoulder disorders. Measurement of adverse events was reported in only 31% of 
trials. 
 
Strengths and limitations 
A strength of our study is the inclusion of trials investigating a diverse set of interventions for 
an array of shoulder disorders, which enhances the generalisability of the findings. In 
addition, the majority of our sample of trials was identified from published Cochrane 
reviews, each of which used a comprehensive search strategy and methods to minimise error 
in trial selection. However, some limitations need to be considered. Selective reporting of 
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only the positive/statistically significant outcomes is common in clinical trials (26), and so by 
relying on what was reported rather than asking trialists about any non-reported domains and 
instruments, we may have underestimated the frequency of outcome domains and instruments 
that were actually measured. Also, rather than updating the searches of each Cochrane review 
on a shoulder disorder, we only searched PubMed for shoulder trials indexed in the last 10 
years. Therefore, it is likely that we have not identified all published trials for shoulder 
disorders. However, we are not aware of any evidence that outcomes measured in trials 
included in Cochrane reviews or indexed in PubMed differ to those in trials indexed 
elsewhere. Therefore, we do not believe our findings are unrepresentative of all shoulder 
trials. 
 
Comparison with other studies 
This review extends the findings of a previous review of physical therapy trials (18) in 
several ways. We included a much larger sample of trials (409 versus 171) addressing a more 
comprehensive set of questions. This led to the identification of 12 domains that were not 
previously recorded, namely: number of deaths, radiographic outcomes, shoulder instability, 
failure of surgery, surgical process outcomes, requiring re-operation or revision surgery, 
satisfaction with treatment services, social functioning, recreation or leisure activity, sleep 
functioning, non-health care service use, and haemodynamic variables. We also identified a 
larger number of measurement instruments for the same domain (for example, 35 pain 
instruments and 29 function instruments were noted in the previous review, compared with 
47 and 49, respectively, in the current sample). Using the OMERACT Filter 2.0 (13) and ICF 
framework (22) to classify domains, we found that slightly more (15/32 versus 11/32) of the 
domains used in shoulder trials were measures of changes in body function and structure that 
accompany the disorder (that is, “Pathophysiological Manifestations” in OMERACT terms or 
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“Body Functions and Structures” in the ICF conceptual model)  rather than measures of 
performance of activities of daily living, work and recreation/leisure (“Life Impact” in 
OMERACT terms or “Activities and Participation” in the ICF conceptual model). Finally, 
measurement of adverse events was reported only slightly more often in the current sample 
(31% versus 27%), suggesting that trials of interventions other than physical therapy are not 
immune from poor harms reporting. 
 
Explanation and implications of study results 
Most of the domains (75%) we identified were measured at a similar frequency across all of 
the included shoulder disorders (including pain, physical function, and range of motion). For 
this reason, we think it will be appropriate to develop a single COS for all shoulder disorders, 
rather than developing different sets for different disorders (i.e. one for rotator cuff disease, 
one for adhesive capsulitis). A single COS would not preclude trialists from measuring other 
domains that might be especially relevant to the context of the trial (13, 27). For example, a 
trial of surgical repair for rotator cuff tear may use imaging to measure integrity of the repair, 
while a trial of an intervention designed to improve shoulder posture may measure 
improvement in posture, and a trial for shoulder instability in young athletes may measure 
time to return to sport. However, we recognise that the decision to create a single COS for all 
shoulder disorders requires consideration from various stakeholders, the most important of 
whom is patients, who can help ensure that the COS sufficiently captures the experience of 
their condition (28). 
 
Government-sponsorship of initiatives such as the Patient-Centered Outcomes Research 
Institute (PCORI) indicates that policy makers have a strong desire for PROMs to be 
collected in clinical trials (29). Previous shoulder trials have done well at measuring patient-
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reported pain, but infrequently measured other potentially important PROMs such as global 
assessment of treatment success, health-related quality of life, work ability, sleep quality and 
psychological functioning. Also, while many patient-reported measures of physical 
functioning were identified across the trials, the most commonly used one – the Constant-
Murley score, used in 31% of trials – includes physician-rated components to measure range 
of motion and strength (impairment measures). It is unclear if trialists believe pain is the only 
necessary PROM to measure in shoulder trials, have concerns about the measurement 
instruments available to measure other PROMs, or believe that non-PROMs such as range of 
motion (measured using a goniometer) or radiographic outcomes are more valid and reliable. 
Many studies have found that PROMs do not correlate well with objectively measured 
outcomes in people with shoulder disorders (30-33), yet provide valuable insight into the 
overall burden that a health condition places on an individual (34). In future, it would be 
valuable to ask different stakeholders for their opinion on the relative value of PROMs and 
non-PROMs for shoulder disorders, and to consider which PROMs are the most essential to 
include in a COS for shoulder disorders. 
 
Additional research is needed before we can recommend a COS for shoulder disorders, and 
the results of this literature review should therefore be considered preliminary only. It is 
possible that the outcome domains previously measured in shoulder trials do not fully 
represent the lived experience of people with shoulder disorders. Other domains that have 
never been measured in past trials may exist, and could be elicited from patients using 
qualitative methods, such as focus groups and interviews (35). Further, a plethora of 
instruments have been collated in this review, but we have not yet evaluated their 
measurement properties, including construct validity, test-retest reliability, and 
responsiveness. The instruments most frequently used in past trials may not necessarily be the 
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best at reliably detecting change in symptoms/function over time. A systematic review of 
measurement properties of instruments for shoulder disorders will help determine which are 
most fit for purpose. 
 
In conclusion, there is a wide variety of domains and instruments being used in trials for 
various shoulder disorders. The most common domains, consistently measured across all 
trials, were pain, range of motion and physical function. We will use the results of this review 
to inform an international Delphi study to select core domains, and then review the 
measurement properties of applicable instruments. Such research will ultimately lead to the 
creation of a core set of domains and recommended instruments for use in trials for shoulder 
disorders, whose endorsement we will seek from OMERACT. 
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TABLES 
Table 1. Characteristics of included trials 
Characteristic Number (%), 
of 409 trials 
Year of publication  
1954– 2001  90 (22) 
2002 – 2006  55 (13) 
2007 – 2010 103 (25) 
2011 - 2015 161 (39) 
Shoulder disorder  
Rotator cuff disease  186 (45) 
Adhesive capsulitis (frozen shoulder) 97 (24) 
Shoulder instability 31 (8) 
Proximal humeral or humeral head fracture  31 (8) 
Unspecified shoulder pain 30 (7) 
Dislocation of the shoulder 17 (4) 
Glenohumeral or acromioclavicular osteoarthritis 16 (4) 
Mixed (some with rotator cuff disease, others with instability) 1 (0.2) 
Intervention under investigation  
Manual therapy or exercise (or both delivered in combination) 140 (34) 
Surgery (e.g. tendon repair surgery for rotator cuff tear) 104 (25) 
Electrotherapy modalities (e.g. therapeutic ultrasound, laser therapy) 65 (16) 
Glucocorticoid injection 45 (11) 
Platelet-rich plasma therapies 11 (3) 
Acupuncture 8 (2) 
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Oral glucocorticoids 8 (2) 
Intra-articular lignocaine 5 (1) 
Arthrographic distension of the glenohumeral joint with glucocorticoid 
and saline 
4 (1) 
Sodium hyaluronate injection 4 (1) 
Topical glyceryl trinitrate 3 (1) 
Botulinum toxin 3 (1) 
Extracorporeal shockwave therapy 3 (1) 
Continuous interscalene brachial plexus block  2 (0.5) 
Manipulation under anaesthesia 1 (0.2) 
Needling fragmentation irrigation 1 (0.2) 
Radiotherapy 1 (0.2) 
Suprascapular nerve block 1 (0.2) 
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Table 2. OMERACT “Life Impact” (ICF “Activities and Participation”) outcome 
domains in 409 included trials 
Domain (examples in parentheses) Number 
(%) 
Number of 
instruments 
Pain (how much a person’s shoulder hurts overall, during or 
following activity, at night, etc.) 
368 (90) 47 
Physical functioning (ability to carry out physical activities of 
daily living such as dressing, bathing) 
289 (71) 49 
Global assessment of treatment success (person’s assessment 
of their recovery or degree of improvement) 
62 (15) 9 
Health-related quality of life (physical, psychological and 
social domains of health) 
62 (15) 12 
Satisfaction with treatment services (person’s satisfaction 
with care received) 
61 (15) 6 
Social functioning (ability to engage in normal social activities 
with family, friends) 
29 (7) 2 
Work ability (ability to meet physical or psychological 
demands of work) 
24 (6) 4 
Recreation and leisure activity (ability to engage in 
recreational or leisure activities, including sports) 
22 (5) 7 
Psychological functioning (depression, anxiety) 18 (4) 10 
Severity of the main complaint (how much a person’s main 
concern, be it pain or disability, bothers them) 
5 (1) 1 
Sleep functioning (impact of disorder on onset, maintenance, 
quality and amount of sleep) 
2 (0.5) 2 
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Table 3. OMERACT “Pathophysiological Manifestations” (ICF “Body Functions and 
Structures”) outcome domains in 409 included trials 
Domain (examples in parentheses) Number 
(%) 
Number of 
instruments 
Range of motion (distance and direction that the shoulder is 
able to move, for example, in flexion or abduction, either when 
initiated by the person or guided by the care provider) 
320 (78) 25 
Muscle strength (force generated by the contraction of a 
shoulder muscle) 
178 (44) 38 
Radiographic outcomes (any measure of the structure of the 
bones/joints/tendons measured via imaging, such as rotator cuff 
repair integrity, acromiohumeral distance) 
86 (21) 46 
Shoulder instability (loosening of connective tissue 
surrounding the shoulder joint, which can sometimes result in 
the head of the upper arm bone slipping out of the shoulder 
socket) 
25 (6) 3 
Failure of surgery (inability of the surgery to correct a 
specific structural problem, such as malunion of a fracture after 
surgery) 
24 (6) 8 
Testing positive on specific tests during physical 
examination (e.g. painful arc test for rotator cuff disease, 
relocation test for shoulder instability) 
21 (5) 8 
Surgical process outcomes (measures of the implementation 
of a surgical intervention) 
20 (5) 7 
Pain on palpation (pain following touch of any muscle, 7 (2) 1 
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Domain (examples in parentheses) Number 
(%) 
Number of 
instruments 
tendon and bony prominences of the shoulder region) 
Scapular dysfunction (problems with rotating the scapular or 
poor motor control of the scapular)  
7 (2) 8 
Proprioception of the shoulder (person’s sense of position 
and movement of the shoulder) 
5 (1) 2 
Muscle tone (slight tension or firmness present in resting 
muscles of the shoulder) 
4 (1) 7 
Shoulder posture (position in which shoulder is held upright 
against gravity while standing, sitting or lying down) 
2 (0.5) 1 
Weakness on movement (person’s sense that more effort than 
normal is required to move the shoulder) 
1 (0.2) 1 
Shoulder swelling (abnormal enlargement caused by 
accumulation of fluid in the shoulder joint) 
1 (0.2) 1 
Haemodynamic variables (any measure of blood flow, such 
as blood pressure or heart rate) 
1 (0.2) 1 
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Table 4. OMERACT “Resource Use” outcome domains in 409 included trials 
Domain (examples in parentheses) Number 
(%) 
Number of 
instruments 
Requiring re-operation or revision surgery (use of additional 
surgical procedures following failure of the first attempt) 
35 (9) 1 
Health care services (health care visits, laboratory tests, 
imaging, days of admission to a hospital, medications)  
29 (7) 4 
Non-health care services (visits to professionals of alternative 
medicine, over-the-counter medications, patient's time and 
travel expenses) 
29 (7) 4 
Work productivity (economic impact of absenteeism due to 
shoulder disorder) 
23 (6) 2 
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FIGURE LEGENDS 
 
Figure 1. Flow diagram of identification, screening, and inclusion of trials 
SR = systematic review 
 
Figure 2. Percentage of trials measuring the most commonly measured domains, sub-grouped 
by shoulder disorder. Values are percentages. AC = adhesive capsulitis, HRQoL = health-
related quality of life, RCD = rotator cuff disease OA = osteoarthritis 
 
 
 
